Journal Article

A Randomised Controlled Trial of Intravenous Zoledronic Acid in Malignant Pleural Disease: A Proof of Principle Pilot Study

Zahan-Evans, Natalie, Braybrooke, Jeremy P., Maskell, Nick A., Lyburn, Iain, Hooper, Clare E., Lyen, Stephen M., Sequeiros, Iara, Kahan, Brennan C., Morley, Anna J., Clive, Amelia O., Edey, Anthony J., Milton, Tim, Hall, David, White, Paul

2015

Overview

Animal studies have shown Zoledronic Acid (ZA) may diminish pleural fluid accumulation and tumour bulk in malignant pleural disease (MPD). We performed a pilot study to evaluate its effects in humans. We undertook a single centre, double-blind, placebo-controlled trial in adults with MPD. Patients were randomised (1:1) to receive 2 doses of intravenous ZA or placebo, 3 weeks apart and were followed-up for 6 weeks. The co-primary outcomes were change in Visual Analogue Scale (VAS) score measured breathlessness during trial follow-up and change in the initial area under the curve (iAUC) on thoracic Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE-MRI) from randomisation to week 5. Multiple secondary endpoints were also evaluated. Between January 2010 and May 2013, 30 patients were enrolled, 24 randomised and 4 withdrew after randomisation (1 withdrew consent; 3 had a clinical decline). At baseline, the ZA group were more breathless, had more advanced disease on radiology and worse quality of life than the placebo group. There was no significant difference between the groups with regards change in breathlessness (Adjusted mean difference (AMD) 4.16 (95%CI -4.7 to 13.0)) or change in DCE-MRI iAUC (AMD -15.4 (95%CI -58.1 to 27.3). Two of nine (22%) in the ZA arm had a >10% improvement by modified RECIST (vs 0/11 who received placebo). There was no significant difference in quality of life measured by the QLQ-C30 score (global QOL: AMD -4.1 (-13.0 to 4.9)), side effects or serious adverse event rates. This is the first human study to evaluate ZA in MPD. The study is limited by small numbers and imbalanced baseline characteristics. Although no convincing treatment effect was identified, potential benefits for specific subgroups of patients cannot be excluded. This study provides important information regarding the feasibility of future trials to evaluate the effects of ZA further. UK Clinical Research Network ID 8877 ISRCTN17030426 www.isrctn.com.

• Publisher: Public Library of Science,Public Library of Science (PLoS)
• Subject: Acids / Administration, Intravenous / Adults / Aged / Biomarkers - metabolism / Bone disorder agents / Breast cancer / Cancer therapies / Chemotherapy / Clinical trials / Consent / Diagnostic imaging / Diphosphonates - administration & dosage / Diphosphonates - adverse effects / Diphosphonates - pharmacology / Diphosphonates - therapeutic use / Disease control / Dyspnea - complications / Feasibility studies / Female / Humans / Imidazoles - administration & dosage / Imidazoles - adverse effects / Imidazoles - pharmacology / Imidazoles - therapeutic use / Intravenous administration / Lung cancer / Magnetic resonance / Magnetic resonance imaging / Male / Medical research / Mesothelioma / Neoplasm Metastasis - pathology / Oncology / Patients / Pilot Projects / Pleura - drug effects / Pleura - pathology / Pleural Effusion, Malignant - complications / Pleural Effusion, Malignant - drug therapy / Pleural Effusion, Malignant - metabolism / Pleural Effusion, Malignant - pathology / Pleural fluid / Quality of Life / Radiology / Randomization / Safety / Side effects / Subgroups / Thorax / Treatment Outcome / Tumors / Zoledronic acid